Literature DB >> 16709798

Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells.

Sandrine Benhamron1, Hovav Nechushtan, Inna Verbovetski, Alon Krispin, Ghada Abboud-Jarrous, Eyal Zcharia, Evgeny Edovitsky, Efrat Nahari, Tamar Peretz, Israel Vlodavsky, Dror Mevorach.   

Abstract

After Ag capture and exposure to danger stimuli, maturing dendritic cells (DCs) migrate to regional lymph nodes, where antigenic peptides are presented to T lymphocytes. To migrate from peripheral tissue such as the epidermis to regional lymph nodes, Ag-bearing epidermal Langerhans cells must move through an extracellular matrix (ECM) of various compositions. The nature of their capacity to transmigrate via ECM is not well understood, although MIP-3beta and CCR7 play critical roles. We were interested in verifying whether heparanase, a heparan sulfate-degrading endo-beta-d-glucuronidase that participates in ECM degradation and remodeling, is expressed and functional in monocyte-derived DCs. Using immunohistochemistry, confocal microscopy, RT-PCR, Western blot analysis, assays for heparanase activity, and Matrigel transmigration, we show that heparanase is expressed in both nuclei and cytoplasm of immature DCs, and that gene expression and synthesis take place mainly in monocytes and early immature DCs. We also found that both nuclear and cytoplasm fractions show heparanase activity, and upon LPS-induced maturation, heparanase translocates to the cell surface and degrades ECM heparan sulfate. Matrigel transmigration assays showed a MIP-3beta-comparable role for heparanase. Because heparan sulfate glycosaminoglycans play a key role in the self-assembly, insolubility, and barrier properties of the ECM, the results of this study suggest that heparanase is a key enzyme in DC transmigration through the ECM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709798     DOI: 10.4049/jimmunol.176.11.6417

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  The Role of Heparan Sulfate in Inflammation, and the Development of Biomimetics as Anti-Inflammatory Strategies.

Authors:  Brooke L Farrugia; Megan S Lord; James Melrose; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

2.  Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

Authors:  Menachem Bitan; Lola Weiss; Israel Reibstein; Michael Zeira; Yakov Fellig; Shimon Slavin; Eyal Zcharia; Arnon Nagler; Israel Vlodavsky
Journal:  Mol Immunol       Date:  2010-06       Impact factor: 4.407

3.  Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP.

Authors:  Olga Ostrovsky; Avichai Shimoni; Polina Baryakh; Yan Morgulis; Margarita Mayorov; Katia Beider; Anna Shteingauz; Neta Ilan; Israel Vlodavsky; Arnon Nagler
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

4.  Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Authors:  Karène Mahtouk; Dirk Hose; Pierre Raynaud; Michael Hundemer; Michel Jourdan; Eric Jourdan; Veronique Pantesco; Marion Baudard; John De Vos; Marion Larroque; Thomas Moehler; Jean-Francois Rossi; Thierry Rème; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

Review 5.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

6.  Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics.

Authors:  Daiki Iwami; C Colin Brinkman; Jonathan S Bromberg
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

Review 7.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

Review 8.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 9.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

10.  HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.

Authors:  Ting Chen; Xu-Dong Tang; Yin Wan; Ling Chen; Song-Tao Yu; Zhen Xiong; Dian-Chun Fang; Guang-Ping Liang; Shi-Ming Yang
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.